<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Venus Medtech Hangzhou Inc — News on 6ix</title>
    <link>https://6ix.com/company/venus-medtech-hangzhou-inc</link>
    <description>Latest news and press releases for Venus Medtech Hangzhou Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sat, 25 Oct 2025 07:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/venus-medtech-hangzhou-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement</title>
      <link>https://6ix.com/company/venus-medtech-hangzhou-inc/news/cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement</link>
      <guid isPermaLink="true">https://6ix.com/company/venus-medtech-hangzhou-inc/news/cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement</guid>
      <pubDate>Sat, 25 Oct 2025 07:00:00 GMT</pubDate>
      <description>Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the &quot;Company&quot;) today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve&apos;s Transcatheter Tricuspid Valve Replacement (TTVR) system, the company&apos;s flagship solution for treating tricuspid regurgitat</description>
    </item>
    <item>
      <title>Court Sides with Cardiovalve in Edwards patent spat</title>
      <link>https://6ix.com/company/venus-medtech-hangzhou-inc/news/court-sides-with-cardiovalve-in-edwards-patent-spat</link>
      <guid isPermaLink="true">https://6ix.com/company/venus-medtech-hangzhou-inc/news/court-sides-with-cardiovalve-in-edwards-patent-spat</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
      <description>Venus Medtech (Hangzhou) Inc. (&quot;Venus Medtech&quot;, Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. (&quot;Cardiovalve&quot;) against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. (collectively &quot;Edwards&quot;). The United States Court of Appeals for the Federal Circuit (&quot;CAFC&quot;) has formally issued its mandate in Case 23-1515, affirming the Patent Trial and Appeal Board&apos;s (&quot;PTAB&quot;) December 2022 ruling that upheld the validity of Car</description>
    </item>
    <item>
      <title>Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations</title>
      <link>https://6ix.com/company/venus-medtech-hangzhou-inc/news/venus-medtech-reports-2024-annual-results-profitability-surges-with-robust-global-expansion-and-innovations</link>
      <guid isPermaLink="true">https://6ix.com/company/venus-medtech-hangzhou-inc/news/venus-medtech-reports-2024-annual-results-profitability-surges-with-robust-global-expansion-and-innovations</guid>
      <pubDate>Tue, 22 Apr 2025 01:00:00 GMT</pubDate>
      <description>Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as &quot;Venus Medtech&quot; or the &quot;Company&quot;), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 (&quot;the Year&quot;), demonstrating significant improvements in profitability and operational discipline despite market challenges.</description>
    </item>
  </channel>
</rss>